InMed Pharmaceuticals (INM) EBIAT (2021 - 2025)
Historic EBIAT for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to -$2.0 million.
- InMed Pharmaceuticals' EBIAT rose 2123.48% to -$2.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$7.7 million, marking a year-over-year increase of 356.73%. This contributed to the annual value of -$8.2 million for FY2025, which is 649.35% down from last year.
- As of Q4 2025, InMed Pharmaceuticals' EBIAT stood at -$2.0 million, which was up 2123.48% from -$1.7 million recorded in Q3 2025.
- In the past 5 years, InMed Pharmaceuticals' EBIAT ranged from a high of -$338391.0 in Q2 2023 and a low of -$7.9 million during Q2 2022
- Moreover, its 5-year median value for EBIAT was -$2.1 million (2022), whereas its average is -$2.6 million.
- In the last 5 years, InMed Pharmaceuticals' EBIAT soared by 9570.03% in 2023 and then crashed by 47983.84% in 2024.
- Quarter analysis of 5 years shows InMed Pharmaceuticals' EBIAT stood at -$4.3 million in 2021, then skyrocketed by 50.94% to -$2.1 million in 2022, then grew by 29.65% to -$1.5 million in 2023, then plummeted by 74.2% to -$2.6 million in 2024, then grew by 21.23% to -$2.0 million in 2025.
- Its EBIAT was -$2.0 million in Q4 2025, compared to -$1.7 million in Q3 2025 and -$1.8 million in Q2 2025.